Abstract:Antibody-drug conjugates (also known as “immunoconjugates”) have only recently entered the arsenal of anticancer drugs, but the number of undergoing clinical trials including them is ever increasing and most therapeutic antibodies are now patented including their potential immunoconjugate derivatives. They typically consist of three components: antibody, linker, and cytotoxin. An antibody or antibody fragment targeted to a tumor-associated antigen acts as a carrier for drug delivery and can be conjugated by cleavable or uncleavable linkers to a variety of effector molecules, either a drug, toxin, radioisotope, enzyme (the latter also used in Antibody-Directed Enzyme Prodrug Therapy), or to drug-containing liposomes or nanoparticles. In this review, we propose a general outline of the field, starting from the diagnostic and clinical applications of this class of molecules. Special attention will be devoted to the principles and issues in molecular design (choice of tumor-associated antigen, critical milestones in antibody development, available alternatives for linkers and effector molecule, and strategies for fusion proteins building) to the importance of antibody affinity modulation to optimize therapeutic effect and the potential of emerging alternative scaffolds. Most of the power of these molecules is to reach high concentrations in the tumor, relatively unaffecting normal cells, although one drawback lies in their short half-life. In this respect, modifications of immunoconjugates, which have shown to strongly influence pharmacokinetics, like glycosylation and PEGylation, will be discussed. Undergoing clinical trials and active patents will be analyzed and problems present in clinical use will be reported.

Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy

Aptamers: an Emerging Navigation Tool of Therapeutic Agents for Targeted Cancer Therapy

Novel Insights into the Role of Aptamers in the Fight Against Cancer.

Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy

Tumor-Targeted Drug Delivery With Aptamers

Aptamer-drug Conjugation for Targeted Tumor Cell Therapy.

Recent advances in aptamer-based targeted drug delivery systems for cancer therapy

Aptamer-conjugated Nanomaterials for Specific Cancer Cell Recognition and Targeted Cancer Therapy.

Aptamers as an approach to targeted cancer therapy

Aptamer-guided Selective Delivery of Therapeutics to Breast Cancer Cells Expressing Specific Biomarkers

Nucleic Acid Aptamers: an Emerging Frontier in Cancer Therapy

Aptamers in cancer therapy: problems and new breakthroughs

Aptamer as a targeted approach towards treatment of breast cancer

Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Nucleic Acid Aptamer-Guided Cancer Therapeutics and Diagnostics: the Next Generation of Cancer Medicine

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule

Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery

Targeted Drug Delivery Using Immunoconjugates: Principles and Applications

Aptamer–Gemcitabine Conjugates with Enzymatically Cleavable Linker for Targeted Delivery and Intracellular Drug Release in Cancer Cells